Sinopharm Tech Holdings Limited (stock code: 08156) published its monthly return for the period ended 31 January 2026. The announcement highlights that the total authorized share capital remains at HKD 200,000,000, comprising 12.8 billion ordinary shares of par value HKD 0.0125 each and 3.2 billion non-voting convertible preference shares of par value HKD 0.0125 each.

The issued share capital of 633,693,055 ordinary shares and 1,480,151,050 preference shares remains unchanged during the reporting period, and there are no treasury shares in issue. The company confirms compliance with the public float requirement of 25%.

Under its 2021 Share Option Scheme, 5,280,000 share options were outstanding as of the prior month’s close, and the same number remained outstanding at the end of January 2026. No new ordinary shares were issued during this period under the scheme.

The company also has convertible preference shares with a total principal amount of HKD 148,015,105, convertible at HKD 0.1 per share. These preference shares are convertible at the holder’s option within 10 years from the date of issue, at a ratio of 1:1 into ordinary shares. No related conversions were recorded during January 2026.

The filing states that all relevant compliance measures under the Listing Rules and other regulatory requirements have been met.